A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Trial Profile

A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs BMS 986016 (Primary) ; Nivolumab (Primary) ; Ipilimumab
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms FRACTION-RCC
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 30 Jun 2017 Planned number of patients changed from 650 to 200.
    • 07 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 21 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top